+

WO2008030964A3 - Use of noncalcium zeolites with added calcium salt in hemostatic devices and products - Google Patents

Use of noncalcium zeolites with added calcium salt in hemostatic devices and products Download PDF

Info

Publication number
WO2008030964A3
WO2008030964A3 PCT/US2007/077763 US2007077763W WO2008030964A3 WO 2008030964 A3 WO2008030964 A3 WO 2008030964A3 US 2007077763 W US2007077763 W US 2007077763W WO 2008030964 A3 WO2008030964 A3 WO 2008030964A3
Authority
WO
WIPO (PCT)
Prior art keywords
zeolites
noncalcium
products
calcium salt
added calcium
Prior art date
Application number
PCT/US2007/077763
Other languages
French (fr)
Other versions
WO2008030964A2 (en
Inventor
Robert L Bedard
Original Assignee
Uop Llc
Robert L Bedard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uop Llc, Robert L Bedard filed Critical Uop Llc
Priority to CN200780033033A priority Critical patent/CN101677848A/en
Priority to EP07841971A priority patent/EP2059187A2/en
Publication of WO2008030964A2 publication Critical patent/WO2008030964A2/en
Publication of WO2008030964A3 publication Critical patent/WO2008030964A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

It is known that calcium exchanged zeolites are effective in hemostasis. The reason that Ca-exchanged zeolites are required has not been explained in the prior art, except that the presence of Ca2+ ions are important in the clotting mechanism. It has now been found that the addition of Ca2+ ions alone actually slow clotting of blood. The use of Ca-zeolites appear to be effective in hemostasis simply because they don't remove the critical Ca2+ from the blood by ion exchange. A NaA zeolite with an effective amount of added Ca2+ salt is nearly equally active in coagulation as the Ca-exchanged form of CaA zeolite.
PCT/US2007/077763 2006-09-08 2007-09-06 Use of noncalcium zeolites with added calcium salt in hemostatic devices and products WO2008030964A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN200780033033A CN101677848A (en) 2006-09-08 2007-09-06 Use of noncalcium zeolites with added calcium salt in hemostatic devices and products
EP07841971A EP2059187A2 (en) 2006-09-08 2007-09-06 Use of noncalcium zeolites with added calcium salt in hemostatic devices and products

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53036906A 2006-09-08 2006-09-08
US11/530,369 2006-09-08

Publications (2)

Publication Number Publication Date
WO2008030964A2 WO2008030964A2 (en) 2008-03-13
WO2008030964A3 true WO2008030964A3 (en) 2008-05-08

Family

ID=39158050

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/077763 WO2008030964A2 (en) 2006-09-08 2007-09-06 Use of noncalcium zeolites with added calcium salt in hemostatic devices and products

Country Status (3)

Country Link
EP (1) EP2059187A2 (en)
CN (1) CN101677848A (en)
WO (1) WO2008030964A2 (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008202A (en) * 1988-11-29 1991-04-16 Sequoia Turner Corporation Blood diluent for red blood cell analysis
US5861146A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Method for reducing body odor
US5863581A (en) * 1996-04-25 1999-01-26 Lipton, Division Of Conopco, Inc. Tea processing with zeolites
US6100414A (en) * 1998-04-02 2000-08-08 Eastman Chemical Company Cyclopentadienyl transition metal compounds useful as polymerization catalysts
US6521265B1 (en) * 2000-02-09 2003-02-18 Biolife, L.L.C. Method for applying a blood clotting agent
US20030133990A1 (en) * 2000-10-13 2003-07-17 Hursey Francis X. Bandage using molecular sieves
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
US20040258826A1 (en) * 2001-12-20 2004-12-23 Navarro Y Koren Peter Antonio Matrix-forming composition containing pectin
US20050074505A1 (en) * 2003-09-12 2005-04-07 Hursey Francis X. Calcium zeolite hemostatic agent
US20060178609A1 (en) * 2005-02-09 2006-08-10 Z-Medica, Llc Devices and methods for the delivery of molecular sieve materials for the formation of blood clots

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008202A (en) * 1988-11-29 1991-04-16 Sequoia Turner Corporation Blood diluent for red blood cell analysis
US5863581A (en) * 1996-04-25 1999-01-26 Lipton, Division Of Conopco, Inc. Tea processing with zeolites
US5861146A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Method for reducing body odor
US6100414A (en) * 1998-04-02 2000-08-08 Eastman Chemical Company Cyclopentadienyl transition metal compounds useful as polymerization catalysts
US6521265B1 (en) * 2000-02-09 2003-02-18 Biolife, L.L.C. Method for applying a blood clotting agent
US20030133990A1 (en) * 2000-10-13 2003-07-17 Hursey Francis X. Bandage using molecular sieves
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
US20040258826A1 (en) * 2001-12-20 2004-12-23 Navarro Y Koren Peter Antonio Matrix-forming composition containing pectin
US20050074505A1 (en) * 2003-09-12 2005-04-07 Hursey Francis X. Calcium zeolite hemostatic agent
US20060178609A1 (en) * 2005-02-09 2006-08-10 Z-Medica, Llc Devices and methods for the delivery of molecular sieve materials for the formation of blood clots

Also Published As

Publication number Publication date
CN101677848A (en) 2010-03-24
WO2008030964A2 (en) 2008-03-13
EP2059187A2 (en) 2009-05-20

Similar Documents

Publication Publication Date Title
Pourshahrestani et al. Gallium-containing mesoporous bioactive glass with potent hemostatic activity and antibacterial efficacy
NZ574653A (en) Solid dressing for treating wounded tissue
WO2007141278A3 (en) Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
WO2007141274A3 (en) Human binding molecules having killing activity against staphylococci and uses thereof
WO2009042962A3 (en) Antidotes for factor xa inhibitors and methods of using the same
IL186907A0 (en) 4-(pyridin-3-yl)-2-(pyridin-2-yl)-1,2-dihydro-3h-pyrazol-3-one derivatives as specific hifprolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases
WO2008131154A3 (en) Fibrin compositions containing strontium compounds
BR112012030037A2 (en) oral therapeutic composition
MX2012007922A (en) Dry powder fibrin sealant.
WO2008127497A3 (en) Hemostatic compositions and methods of use
NZ596583A (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
WO2012122044A3 (en) Flowable collagen-based hemostat and methods of use
WO2008073479A3 (en) Anticonnexin polynucleotides as impaired wound healing compositions
WO2012129161A3 (en) Stabilized hypohalous acid solutions
WO2007093539A3 (en) Benzoyl-substituted alanines
WO2007015107A3 (en) Artificial platelets
BRPI0607031A2 (en) synergistically combination of fungicidal active compounds
WO2008128149A3 (en) Providing hemostasis in anticoagulated blood by using zeolites
WO2005086836A3 (en) Ion channel modulators
UA117504C2 (en) (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis
WO2007120374A3 (en) Anti-arenaviral compounds
WO2014081618A1 (en) Thrombin inhibitors
WO2007126363A3 (en) Antisecretory protein for use in the treatment of compartment syndrome
EP2653166A3 (en) Pharmaceutical composition and related methods
HRP20230336T1 (en) Anti-hemorrhaging compositions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780033033.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07841971

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007841971

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2228/DELNP/2009

Country of ref document: IN

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载